Escolar Documentos
Profissional Documentos
Cultura Documentos
Pharmacy
ICH
is a joint initiative involving both regulators and industry as equal partners in the scientific and technical discussions of the testing procedures which are required to ensure and assess the safety, quality, efficacy, and multidisciplinary of medicines.
ICH
ICH TOPICS
QUALITY (Q) SAFETY (S) EFFICACY (E) MULTI DISCIPLINARY (M)
Harmonization Achievements In the quality area include Pivotal milestones such as the conduct of stability studies. defining relevant thresholds for impurities testing and a more flexible approach to pharmaceutical quality based on good manufacturing practice(GMP) risk management
EFFICACY GUIDELINES
E2D Post Approval safety Data Management : Definitions and Standards for Expedited Reporting
This guide line has been finalized on Nov 2003 It provides a standardized procedure for Post Approval safety Data Management : Definitions and standards for Expedited Reporting To relevant authority
It is intended to aid in planning pharmacovigilance activities, especially in preparation for the early post marketing period of a new drug
MULTIDISCIPLINARY GUIDELINES
MULTIDISCIPLINARY GUIDELINES
It includes the ICH medical terminology, the Common Technical Document (CTD) and the development of Electronic Standards for the Transfer of Regulatory Information(ESTRI)
MedDRA Terminology M1
Electronic Standards M2 ESTRI: Electronic Standards for the Transfer of Regulatory Information
Objective of facilitating international electronic communication by evaluating and recommending for the requirements of the pharmaceutical companies and regulatory authorities
Nonclinical safety studiesM3 Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals It was approved on June 2009 It represents the consensus that exists regarding the type and duration of non clinical safety studies and their timing to support the conduct of human clinical trials and marketing authorisation for pharmaceuticals
Data Elements and Standards for Drug Dictionaries M5 It was approved on 2004
Gene Therapy M6 Virus and Gene therapy vector shedding and Transmission It was approved on 2009
It provides recommendations to industry and Regulators on non clinical and clinical studies and guidance on use of analytical assays for the detection and characterization of shed virus
Genetoxic Impurities M7
Assessment and control of DNA Reactive impurities in pharmaceuticals to limit potential carcinogenic Risk It was approved in June 2010 It was proposed to offer guidance on analysis of structure activity relationships for genotoxicity